StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOLFree Report) in a research note published on Friday. The firm issued a sell rating on the medical technology company’s stock.

Several other equities analysts have also weighed in on the company. Maxim Group lowered BIOLASE from a strong-buy rating to a hold rating in a report on Friday, May 24th. Benchmark reissued a speculative buy rating and issued a $0.40 price objective on shares of BIOLASE in a research note on Tuesday, May 14th.

Get Our Latest Report on BIOLASE

BIOLASE Stock Performance

Shares of BIOL stock opened at $0.05 on Friday. BIOLASE has a fifty-two week low of $0.04 and a fifty-two week high of $10.31. The stock’s 50-day moving average is $0.15 and its two-hundred day moving average is $0.43. The company has a debt-to-equity ratio of 34.06, a current ratio of 1.17 and a quick ratio of 0.64. The firm has a market cap of $1.55 million, a P/E ratio of 0.00 and a beta of 0.74.

BIOLASE (NASDAQ:BIOLGet Free Report) last issued its quarterly earnings data on Monday, May 13th. The medical technology company reported ($0.36) earnings per share for the quarter. The business had revenue of $10.13 million for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%.

Institutional Trading of BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC raised its position in BIOLASE, Inc. (NASDAQ:BIOLFree Report) by 1,068.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. Institutional investors own 8.79% of the company’s stock.

About BIOLASE

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

See Also

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.